ArticleChemMedChem2026
Structure-Guided Identification of GPR84 Ligand Candidates With Potential Immunomodulatory Activities.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
GPR84, a medium-chain fatty acid (MCFA)-sensing G protein-coupled receptor, plays a significant role in immune regulation. Despite its therapeutic potential, structurally diverse and well-characterized chemical probes of GPR84 remain limited. In the current study, we developed a novel structure-guided and dual-route pipeline to explore and prioritize small-molecule scaffolds compatible with the GPR84 orthosteric pocket, with pharmacophore-based ZINC screening and LigBuilder-based de novo design, accompanied by molecular docking, ADME filtering, and molecular dynamics, followed by immunoregulatory activity validation. ZINC screening identified ZINC149375 (SC787) and ZINC76994316 (Z109), which were further evaluated by 500-ns molecular dynamics simulations. Additionally, LIG081 and LIG133 from the LigBuilder-derived series emerged as computationally prioritized de novo candidates with favorable and persistent predicted interactions within the GPR84 orthosteric pocket. These ZINC-derived compounds demonstrated potent immune cell-dependent immunomodulatory activities associated with GPR84 functional agonism. SC787 and Z109 promote proinflammatory signaling in macrophages while suppressing activation and effector cytokine production in activated CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.